Personalized Allergy Treatment and Research Platform

Publication ID: 24-11857623_0010_PTD

Published: October 28, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized Allergy Treatment and Research Platform,” Published Technical Disclosure No. 24-11857623_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857623_0010_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,623.

Summary of the Inventive Concept

A comprehensive system for personalized allergy treatment, prediction, and research, leveraging advanced computational models, machine learning, and crowdsourced data to revolutionize the field of allergy treatment and prevention.

Background and Problem Solved

The original pan-antiallergy vaccine patent, while a significant breakthrough, has limitations in terms of its broad, non-specific approach to treating allergies. The new inventive concept addresses these limitations by envisioning a next-generation platform that integrates personalized genetic information, advanced computational models, and real-time monitoring to provide tailored treatment and prevention strategies.

Detailed Description of the Inventive Concept

The inventive concept comprises a system for personalized allergy treatment, comprising a database of genetic information, a module for identifying specific IgE motifs associated with an individual's allergies, and a module for generating a customized protein construct based on the identified motifs. Additionally, the system includes a method for predicting the efficacy of an allergy vaccine, a device for real-time monitoring of IgE levels, a computer-implemented method for designing novel protein scaffolds, and a system for crowdsourced allergy research. These components work in concert to provide a comprehensive platform for allergy treatment, prevention, and research.

Novelty and Inventive Step

The new claims introduce a paradigm shift in allergy treatment by leveraging advanced computational models, machine learning, and crowdsourced data to provide personalized, tailored solutions. The inventive concept's novelty lies in its integration of these components to create a comprehensive platform that addresses the limitations of the original pan-antiallergy vaccine patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include variations in the computational models used, the types of data collected and shared, and the specific applications of the platform in different industries, such as pharmaceuticals, biotechnology, and healthcare.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the allergy treatment and prevention market, with potential applications in pharmaceuticals, biotechnology, and healthcare. The platform's ability to provide personalized, tailored solutions could revolutionize the field and create new opportunities for companies and researchers.

CPC Classifications

Section	Class	Group
A	A61	A61K39/395
A	A61	A61K2039/544
A	A61	A61K2039/555

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Immunology, protein engineering, and computational biotechnology, with expertise in vaccine design, protein scaffold modification, and computational modeling of immunological interactions

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or bioengineering, proficient in computational modeling, protein structure analysis, machine learning techniques, and immunological epitope identification

Obviousness Rationale

A PHOSITA would recognize that the personalized allergy treatment platform represents a predictable extension of the pan-antiallergy vaccine patent by applying known computational techniques to customize protein constructs. The core innovation of modifying protein scaffolds with specific IgE motifs is directly suggested by the source patent's computational protein modification approach. The additional layers of machine learning, genetic analysis, and real-time monitoring represent standard technological progressions in personalized medicine and biotechnology.

Obvious Combinations & Variations

Source Patent Element

Protein construct with scaffold segment modified by insertion of a motif segment

PTD Variation

Personalized protein construct generation using machine learning algorithms to predict optimal scaffold-motif combinations

Obviousness Reasoning

Predictable application of computational design techniques to extend the source patent's protein modification methodology, representing a routine optimization approach in protein engineering

Source Patent Element

Computer modeling of scaffold proteins from extracellular adherence protein domain

PTD Variation

Expanded computational modeling to include genetic information analysis and immune response simulation

Obviousness Reasoning

Natural progression of computational techniques, using known machine learning approaches to enhance protein design and predictive modeling

Source Patent Element

IgE motif insertion into protein scaffold

PTD Variation

Real-time IgE level monitoring device integrated with personalized protein construct design

Obviousness Reasoning

Logical combination of known biosensing technologies with protein engineering, representing a predictable solution to personalized medical monitoring

Source Patent Element

Pan-antiallergy vaccine computational approach

PTD Variation

Crowdsourced allergy research platform for collecting and analyzing genetic and immunological data

Obviousness Reasoning

Standard technological evolution of research methodologies, applying big data and collaborative research techniques to expand scientific understanding

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857623 and the disclosed personalized allergy treatment platform, a person of ordinary skill in the art would find the claimed variations obvious. The combination of computational protein design, machine learning, and personalized medical approaches represents a predictable and routine extension of existing immunological engineering techniques, thereby rendering subsequent claims of novelty invalid under 35 U.S.C. § 103.

Original Patent Information

Patent Number	US 11,857,623
Title	Pan-antiallergy vaccine
Assignee(s)	King Abdulaziz University